Lipton RB, Lombard L, Ruff DD, et al. - Researchers sought to determine how lasmiditan, a novel, selective serotonin 5-HT1F receptor agonist developed for acute treatment of migraine, affects migraine disability appraised with the Migraine Disability Assessment (MIDAS) scale for interim data from a long-term safety study. In the 1-year GLADIATOR study, participation was offered to the completers of two single-attack parent studies. The sample comprised 1,978 patients who took ≥ 1 dose of lasmiditan 100 mg or 200 mg and was followed for a median of 288 days. For the lasmiditan 100-mg and 200-mg groups, mean MIDAS scores were 29.4 and 28.9, respectively, at baseline, indicating severe migraine-related disability. Relative to baseline, significantly lower MIDAS total scores were reported at 3, 6, 9, and 12 months for both dose groups. Outcomes there suggest significant reductions in migraine-related disability, including both work or school absenteeism and presenteeism, in correlation with long-term treatment with lasmiditan. The responses in completers and those who dropped out were similar indicating no effect of selective attrition on the improvements. Significant benefits were observed at 3 months that remain maintained through 12 months.